S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
NASDAQ:GLUE

Monte Rosa Therapeutics News Headlines

$18.20
+0.71 (+4.06%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.53
$18.32
50-Day Range
$16.28
$27.15
52-Week Range
$15.67
$45.56
Volume
137,636 shs
Average Volume
202,778 shs
Market Capitalization
$846.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Monte Rosa Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GLUE
News Sentiment

0.07

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GLUE Articles
This Week

1

1

GLUE Articles
Average Week

Get Monte Rosa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.

Monte Rosa Therapeutics (NASDAQ:GLUE) News Headlines Today

SourceHeadline
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Hits New 52-Week Low at $17.00
americanbankingnews.com - December 2 at 11:08 AM
finance.yahoo.com logoMonte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
finance.yahoo.com - December 2 at 8:36 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 4.3%
americanbankingnews.com - December 1 at 12:40 PM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down to $20.55
americanbankingnews.com - November 30 at 11:43 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Up to $17.99
americanbankingnews.com - November 26 at 12:15 PM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year Low at $17.24
americanbankingnews.com - November 25 at 2:38 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6.2%
americanbankingnews.com - November 24 at 12:39 PM
finance.yahoo.com logoMonte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
finance.yahoo.com - November 22 at 9:41 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down to $21.94
americanbankingnews.com - November 18 at 12:41 PM
MarketBeat logoMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - November 17 at 9:40 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Now Covered by Analysts at Berenberg Bank
americanbankingnews.com - November 17 at 8:23 AM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 7.4%
americanbankingnews.com - November 16 at 2:32 PM
MarketBeat logoMonte Rosa Therapeutics (NASDAQ:GLUE) Trading 5.1% Higher
americanbankingnews.com - November 15 at 12:01 PM
MarketBeat logoMonte Rosa Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.57) Per Share (NASDAQ:GLUE)
americanbankingnews.com - November 15 at 3:34 AM
MarketBeat logoFY2021 EPS Estimates for Monte Rosa Therapeutics, Inc. Increased by Analyst (NASDAQ:GLUE)
americanbankingnews.com - November 15 at 1:58 AM
finance.yahoo.com logoMerck KGaA veteran helms immuno-oncology startup with $80M
finance.yahoo.com - November 8 at 3:41 PM
finance.yahoo.com logoMonte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
finance.yahoo.com - October 20 at 8:35 AM
finance.yahoo.com logoMonte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
finance.yahoo.com - October 7 at 9:33 AM
reuters.com logoMonte Rosa Therapeutics Inc
reuters.com - October 4 at 9:35 PM
finance.yahoo.com logoMonte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
finance.yahoo.com - September 30 at 6:32 PM
finance.yahoo.com logoHere's Why We're Not At All Concerned With Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
finance.yahoo.com - September 24 at 1:03 PM
finance.yahoo.com logoMonte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
finance.yahoo.com - September 10 at 5:20 PM
finance.yahoo.com logoMonte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
finance.yahoo.com - September 8 at 3:12 PM
nasdaq.com logoGLUE Crosses Above Average Analyst Target
nasdaq.com - August 25 at 4:42 PM
barrons.com logoMonte Rosa Therapeutics Inc.
barrons.com - August 18 at 1:18 PM
finance.yahoo.com logoMonte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
finance.yahoo.com - August 12 at 4:03 PM
finance.yahoo.com logoMonte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
finance.yahoo.com - August 12 at 4:03 PM
realmoney.thestreet.com logoMonte Rosa Therapeutics, Inc.
realmoney.thestreet.com - August 9 at 12:02 AM
Get Monte Rosa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/9/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.